[
    [
        {
            "time": "",
            "original_text": "东吴证券维持大参林买入评级，2021半年报点评：二季度业绩受疫情影响，门店规模稳步扩张",
            "features": {
                "keywords": [
                    "大参林",
                    "买入评级",
                    "2021半年报",
                    "二季度业绩",
                    "疫情影响",
                    "门店规模",
                    "稳步扩张"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "东吴证券维持大参林买入评级，2021半年报点评：二季度业绩受疫情影响，门店规模稳步扩张",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "大参林2021年中报点评：二季度业绩受疫情影响，门店规模稳步扩张！【东吴医药朱国广团队】",
            "features": {
                "keywords": [
                    "大参林",
                    "2021年中报",
                    "二季度业绩",
                    "疫情影响",
                    "门店规模",
                    "稳步扩张",
                    "东吴医药",
                    "朱国广团队"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "大参林2021年中报点评：二季度业绩受疫情影响，门店规模稳步扩张！【东吴医药朱国广团队】",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "天风证券维持大参林买入评级，半年报点评：门店扩展加速，慢病管理服务促进长期发展",
            "features": {
                "keywords": [
                    "天风证券",
                    "大参林",
                    "买入评级",
                    "半年报",
                    "门店扩展",
                    "加速",
                    "慢病管理",
                    "长期发展"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "天风证券维持大参林买入评级，半年报点评：门店扩展加速，慢病管理服务促进长期发展",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        }
    ]
]